Clinical data management system

Global eClinical Solutions Market Report 2023: Increased Government Grants to Support Clinical Trials Drives Growth

Retrieved on: 
Wednesday, June 28, 2023
Pharma, ECOA, Randomization, Clinical data management system, Clinical trial management system, Electronic trial master file, Electronic data capture, CTMS, CDMS, EDC, Speciality chemicals, Medical imaging, Pharmaceutical industry

Global eClinical Solutions Market, by Pharma and Biopharma Companies, by Region, 2019-2032 (USD Billion)

Key Points: 
  • Global eClinical Solutions Market, by Pharma and Biopharma Companies, by Region, 2019-2032 (USD Billion)
    8.2.1.
  • Global eClinical Solutions Market, by Electronic Clinical Outcome Assessment (ECOA), by Region, 2019-2032 (USD Billion)
    8.4.1.
  • Global eClinical Solutions Market, by Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS), by Region, 2019-2032 (USD Billion)
    8.6.1.
  • Global eClinical Solutions Market, by Clinical Trial Management Systems (CTMS), by Region, 2019-2032 (USD Billion)
    8.9.1.

Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Retrieved on: 
Wednesday, April 26, 2023
EBMT, Haematologica, Hematopoietic stem cell transplantation, Blood, Hospital, Multiple myeloma, AL amyloidosis, Clinical Cancer Research, Hope, Clinical data management system, Hadassah Medical Center, February 9–11, 2017 North American blizzard, Patient, Data, European, CEST, Paper, Liver, LOS, European Society for Medical Oncology, FDA, Safety, IND, BLA, CART, BCMA, Pharmaceutical industry, Semiconductor, Agrochemical, Vaccine, Nursing, Immunotherapy, Amyloidosis

The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).

Key Points: 
  • The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).
  • The new data are being presented during a poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting in Paris, France, April 23-26.
  • “In multiple myeloma, these data are compelling as the overall response rate for ABECMA was 72% in its pivotal KarMMa trial with 100 patients in relapsed or refractory multiple myeloma.
  • Nexcella plans to submit data to the FDA in AL amyloidosis once 30-40 patients are treated with NXC-201.

Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Retrieved on: 
Wednesday, April 26, 2023
EBMT, Haematologica, Hematopoietic stem cell transplantation, Blood, Hospital, Multiple myeloma, AL amyloidosis, Clinical Cancer Research, Hope, Clinical data management system, Hadassah Medical Center, February 9–11, 2017 North American blizzard, Patient, Data, European, CEST, Paper, LOS, Liver, European Society for Medical Oncology, FDA, Safety, IND, BLA, CART, BCMA, Pharmaceutical industry, Semiconductor, Agrochemical, Vaccine, Nursing, Immunotherapy, Amyloidosis

The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).

Key Points: 
  • The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).
  • The new data are being presented during a poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting in Paris, France, April 23-26.
  • “In multiple myeloma, these data are compelling as the overall response rate for ABECMA was 72% in its pivotal KarMMa trial with 100 patients in relapsed or refractory multiple myeloma.
  • Nexcella plans to submit data to the FDA in AL amyloidosis once 30-40 patients are treated with NXC-201.

ConcertAI Presentation at JP Morgan Healthcare Conference Outlines Key Advances in DaaS and AI SaaS Research Platforms for Translational Sciences and Clinical Development

Retrieved on: 
Tuesday, January 10, 2023
Cancer, EBITDA, WES, Sequence, Medicine, American Society of Clinical Oncology, Investment, Caris, RWE, Doctor of Philosophy, Standard of care, JPM, SDV, MS, Research, Social determinants of health, Intelligence cycle, Excellent, Publication, TMB, BMS, FDA, Software as a service, Deletion, Partnership, National Center for Advancing Translational Sciences, RWD, Data as a service, Gold, Icahn Institute for Data Science and Genomic Technology, MSI, AI, GLOH, DACT, Therapy, Health Resources and Services Administration, Senior, Society, Collection, Natural language, Phase II, HRD, NLP, MBA, R, Natural language processing, Patient, Bristol Myers Squibb, Conference, Clinical data management system, Pharmaceutical industry, Management, Medical imaging, Health equity

CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- ConcertAI, LLC ( ConcertAI ), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- ConcertAI, LLC ( ConcertAI ), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.
  • In late 2022, ConcertAI and Caris Life Sciences launched a broadscale reference platform for Translational Sciences, announced publicly on January 9, 2023.
  • The collaboration creates the leading and most comprehensive oncology translational and clinical development multi-modal research data platform aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.
  • This leadership teams' experience and depth of expertise in research, services, and oncology technologies is unprecedented in the industry."

Global eClinical Solutions Market Report (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022
Health, Other Health, Clinical data management system, Adoption, Time, CDMS, Castor, Journal, COVID-19, Clinical data management, Prevalence, CDM, CNY, Population, Growth, Data management, Cros, Forecasting, Clinical trial, DCT, Cancer, Urban, National Bureau of Statistics of China, Solution, Drug development, Research, Marketing, Hospital, Health care, Drug discovery, Hospital Insurance and Diagnostic Services Act, Infection, Conditional sentence, CAGR, Medical imaging, Pharmaceutical industry

A major trend driving this segment is the integration of the CDMS with clinical randomization, supply management, trial, and patient recruitment solutions.

Key Points: 
  • A major trend driving this segment is the integration of the CDMS with clinical randomization, supply management, trial, and patient recruitment solutions.
  • Companies are also developing their existing eClinical tools for extending the capabilities and further easing the whole clinical trial conduction.
  • Several Indian companies are acquiring, partnering, and launching tools in eClinical solutions to strengthen their position on a global and regional level.
  • For Instance, in August 2020, Quantzig launched a comprehensive portfolio of clinical data analytics solutions to strengthen its market position in the global arena.

e-Clinical Solutions Global Market Report 2022: Market is Expected to Grow to $11.60 Billion in 2026 at a CAGR of 13.5% - Long-term Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Technology, Data Management, CDMS, Clinical data management system, Industry, ECOA, Growth, Clinical trial, Hospital, CTMS, Research, EDC, Program, R & D, Drug development, Electronic data capture, Solution, III, Organization, Renewable energy, Pharmaceutical industry, Fine chemical

e-Clinical solutions refer to the use of computerized solutions and related procedures to aid clinical trial operations by automating previously laborious tasks.

Key Points: 
  • e-Clinical solutions refer to the use of computerized solutions and related procedures to aid clinical trial operations by automating previously laborious tasks.
  • The regions covered in the e-clinical solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The e-clinical solutions market research report is one of a series of new reports that provides e-clinical solutions market statistics, including global market size, regional shares, competitors with a e-clinical solutions market share, detailed e-clinical solutions market segments, market trends and opportunities, and any further data you may need to thrive in the e-clinical solutions industry.
  • The countries covered in the e-clinical solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Clinical Data Management Systems Market worth USD 5.4 billion by 2030, says Global Market Insights Inc.

Retrieved on: 
Thursday, July 7, 2022
Cloud, Acquisition, Oracle Corporation, Renewable energy, Solution, USD, Biotechnology, Timothy "Ennovator" Rimbui, Invention, Research, Adoption, CIMS, Dassault Systèmes, Research report, Industry, Clinical data management system, Inflation, CDMS, CAGR, CTMS, Oracle Clinical, Technology, Software, Contract, IBM, Openclinica, Veeva Systems, Fine chemical, Medical device, Pharmaceutical industry

SELBYVILLE, Del., July 7, 2022 /PRNewswire/ -- The clinical data management systems market value is projected to reach USD 5.4 billion by 2030 according to a new research report by Global Market Insights Inc.

Key Points: 
  • SELBYVILLE, Del., July 7, 2022 /PRNewswire/ --The clinical data management systems market value is projected to reach USD 5.4 billion by 2030 according to a new research report by Global Market Insights Inc.
    Pharmaceutical and biopharmaceutical industry has one of the highest R&D expenses worldwide.
  • Thus, to manage overall process of clinical trials, various companies opt for software solution including clinical data management solution to manage the large volume data, thereby augmenting the market expansion.
  • Asia-Pacific clinical data management systems market is estimated to show robust CAGR of 13.8% during the forecast period.
  • With need for effective clinical data and process management tools, the market will foresee immense growth opportunities in Asia Pacific region.

Clinical Data Management Systems Market worth USD 5.4 billion by 2030, says Global Market Insights Inc.

Retrieved on: 
Thursday, July 7, 2022
Cloud, Acquisition, Oracle Corporation, Renewable energy, Solution, USD, Biotechnology, Timothy "Ennovator" Rimbui, Invention, Research, Adoption, CIMS, Dassault Systèmes, Research report, Industry, Clinical data management system, Inflation, CDMS, CAGR, CTMS, Oracle Clinical, Technology, Software, Contract, IBM, Openclinica, Veeva Systems, Fine chemical, Medical device, Pharmaceutical industry

SELBYVILLE, Del., July 7, 2022 /PRNewswire/ -- The clinical data management systems market value is projected to reach USD 5.4 billion by 2030 according to a new research report by Global Market Insights Inc.

Key Points: 
  • SELBYVILLE, Del., July 7, 2022 /PRNewswire/ --The clinical data management systems market value is projected to reach USD 5.4 billion by 2030 according to a new research report by Global Market Insights Inc.
    Pharmaceutical and biopharmaceutical industry has one of the highest R&D expenses worldwide.
  • Thus, to manage overall process of clinical trials, various companies opt for software solution including clinical data management solution to manage the large volume data, thereby augmenting the market expansion.
  • Asia-Pacific clinical data management systems market is estimated to show robust CAGR of 13.8% during the forecast period.
  • With need for effective clinical data and process management tools, the market will foresee immense growth opportunities in Asia Pacific region.

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 21, 2022
PAP, IRB, Letter, Poster, Clinical trial, IND, Association, Clinical data management system, MD, ICT, Food, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Program, Neoplasm, Ernest, Data, Company, CAR, Colorectal cancer, Prostate cancer, Thyroid cancer, American Association, FDA, AACR, RECIST, Medical imaging, Pharmaceutical industry

Pre-Clinical Data demonstrates CoupledCAR technology promotes efficient in vivo expansion and superior functionality of CAR-T cells in a mouse model for prostate cancer.

Key Points: 
  • Pre-Clinical Data demonstrates CoupledCAR technology promotes efficient in vivo expansion and superior functionality of CAR-T cells in a mouse model for prostate cancer.
  • Our two poster presentations demonstrate our CoupledCAR technologys promise of overcoming the typical challenges in treating solid tumors with cellular therapies.
  • Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD.
  • ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer.

CRIO Continues Record Growth for 2021 as Customers Recognize Value and Efficiency Gains of eSource

Retrieved on: 
Wednesday, December 1, 2021
Patient, Cros, Heart, EMR, CEO, Industry, Clinical trial, Solution, SVP, View, ESourcing Capability Model, EDC, CRO, Clinical data management system, Multimedia, DCT, Growth, Pharmaceutical industry, Medical imaging, Online shopping

Highlights for CRIO's breakthrough 2021 include:

Key Points: 
  • Highlights for CRIO's breakthrough 2021 include:
    "The benefits of our eSource offering have really hit home in the life science and CRO industry," said Raymond Nomizu, CEO, CRIO.
  • "We have seen growth in all of our market segments including clinical research sites, sponsors and CROs.
  • Our eSource solutions enable us to streamline clinical research, bringing new medications to market faster for pharma and biotechs."
  • CRIO has established itself as the highest quality and most cost-effective partner for clinical trial data capture.